Table 1.

Demographics and baseline characteristics.

Characteristic	ICI monotherapy N = 40	ICI + nab-paclitaxel N = 17	p value
Median age, years (range)	60 (38–80)	55 (36–72)	0.461
<65 years	33 (82.5%)	14 (82.4%)	0.99
⩾65 years	7 (17.5%)	3 (21.4%)
Sex, n (%)			0.000
Male	31 (77.5%)	14 (82.4%)
Female	9 (22.5%)	3 (17.6%)
Tumor histology, n (%)			0.537
Squamous	14 (35.0%)	4 (23.5%)
Adenocarcinoma	26 (65.0%)	13 (76.5%)
Smoking history, n (%)			0.844
Former or current	19 (47.5%)	10 (58.8%)
Never	20 (50.0%)	7 (41.2%)
Unknown	1(2.5%)	0
Performance status (KPS), n (%)			0.914
90	26 (65.0%)	10 (58.8%)
80	5 (12.5%)	3 (17.6%)
⩽70	9 (22.5%)	4 (23.6%)
EGFR/ALK mutations	14 (35.0%)	5 (29.4%)	0.766
Previous systemic therapy
Platinum-based therapy	40 (100%)	17 (100%)
EGFR TKI	13 (32.5%)	5 (29.4%)	0.682
Anti-angiogenesis therapy	14 (33.3%)	9 (52.9%)	0.207
No. of previous systemic treatments			0.749
1	14 (35.0%)	6 (35.3%)
2	13 (32.5%)	7 (41.2%)
⩾3	13 (32.5%)	4 (23.5%)
Metastatic site
Brain	10 (25.0%)	7 (41.2%)	0.222
Liver	7 (16.7%)	2 (11.8%)	0.714
Bone	14 (35.0%)	4 (23.5%)	0.394

ICI, immune checkpoint inhibitor; KPS, Karnofsky Performance Status; TKI, tyrosine kinase inhibitor